抗寄生蟲藥物市場- 按藥物類型（驅蟲藥、抗原蟲藥、殺體外寄生蟲藥）、給藥途徑（注射劑、口服、局部用藥）、最終用戶（醫院藥房、零售藥房、在線藥房）、全球預測（2024年至2032年）

Antiparasitic Drugs Market - By Drug Type (Anthelmintics, Antiprotozoal, Ectoparasiticide), Route of Administration (Injectable, Oral, Topical), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast (2024 - 2032)

出版日期: 2024年02月06日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年至 2032 年，全球抗寄生蟲藥物市場規模將呈現 5.7% 的CAGR，這得益於全國分銷管道的可及性以及多樣化的選擇。這種廣泛的可用性確保了不同地區的個人能夠輕鬆獲得基本藥物，從而更有效地解決全球寄生蟲疾病的負擔。由於有多種選擇，醫療保健提供者和患者可以靈活地選擇最合適的治療方法，進一步促進行業擴張。例如，2022 年 3 月，May & Baker奈及利亞公司。推出了 Artelum Combo，這是一種針對瘧原蟲的新型藥物，在全國推廣，旨在解決該國的瘧疾負擔。

抗寄生蟲藥物市場根據藥物類型、給藥途徑、最終用戶和地區進行細分。

根據給藥途徑，到 2032 年，口服藥物的行業佔有率將獲得 6% 的CAGR。口服藥物的便利性和有效性使其成為患者和醫療保健提供者的首選。口服製劑也易於給藥，提高患者依從性，吸收更快，從而更快地緩解寄生蟲感染。隨著口服給藥技術的不斷進步和多種口服抗寄生蟲藥物的出現，對口服解決方案的需求將會成長，以應對寄生蟲疾病帶來的全球挑戰。

就最終用戶而言，到 2032 年，零售藥房領域的抗寄生蟲藥物市場CAGR將達到 6.2%，這得益於消費者獲得藥物的便捷性以及零售藥房在當地社區的廣泛存在。最近，尋求抗寄生蟲藥物的患者開始轉向零售藥局以獲得方便的採購和專業建議。此外，自我藥療和非處方藥銷售的成長趨勢將提高人們對這些藥局的偏好，以提供解決寄生蟲感染的便利性和可及性。

由於寄生蟲感染發生率上升、醫療基礎設施擴大以及對治療選擇的認知不斷提高，亞太地區抗寄生蟲藥物行業規模到 2032 年將實現 6.8% 的CAGR。中國、印度和日本等國家處於領先地位，對這些藥物的需求量很大。此外，政府旨在根除寄生蟲病的措施也有所增加。憑藉其多樣化的景觀和龐大的醫療保健需求，亞太地區將成為全球抗寄生蟲藥物產業的主要貢獻者。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 9 章：公司簡介

Bayer AG
Cipla Inc.
Dr. Reddy's Laboratories Ltd,
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd
Ipca Laboratories Ltd.
Mankind Pharma
Merck KGaA
Novartis AG
Sanofi
Zydus Group

簡介目錄

Product Code: 8043

Global Antiparasitic Drugs Market size will demonstrate 5.7% CAGR from 2024 to 2032, driven by their accessibility through nationwide distribution channels coupled with the diverse range of options. This widespread availability ensures that individuals in various regions can easily access essential medications for addressing the global burden of parasitic diseases more effectively. With a multitude of choices available, healthcare providers and patients have the flexibility to select the most suitable treatments, further contributing to the industry expansion. For instance, in March 2022, May & Baker Nigeria Plc. introduced Artelum Combo, a novel medication targeting malaria parasites, with a nationwide rollout aimed at addressing the country's malaria burden.

The antiparasitic drugs market is segmented on the basis of drug type, route of administration, end-user, and region.

Based on route of administration, the industry share from the oral segment will gain 6% CAGR up to 2032. The convenience and effectiveness of oral medications is making them a preferred choice for patients and healthcare providers. Oral formulations also offer ease of administration, improved patient compliance, and quicker absorption, leading to faster relief from parasitic infections. With rising advancements in oral drug delivery technologies and a wide range of oral antiparasitic options available, the need for oral solutions will grow for tackling global challenges posed by parasitic diseases.

In terms of end-user, the antiparasitic drugs market from the retail pharmacy segment will experience 6.2% CAGR through 2032, propelled by convenient access to medications for consumers coupled with the widespread presence of retail pharmacies in local communities. Of late, patients seeking antiparasitic remedies are turning to retail pharmacies for easy procurement and professional advice. Moreover, the rising trend of self-medication and over-the-counter sales will boost the preference for these pharmacies to render convenience and accessibility in addressing parasitic infections.

Asia Pacific antiparasitic drugs industry size will secure a 6.8% CAGR up to 2032, driven by rising incidences of parasitic infections, expanding healthcare infrastructure, and the increasing awareness about treatment options. Countries like China, India, and Japan are at the forefront, witnessing substantial demand for these medications. Additionally, there has been a rise in government initiatives aimed at eradicating parasitic diseases. With its diverse landscape and significant healthcare needs, the APAC region will emerge as a major contributor to the global antiparasitic drugs industry.

Chapter 1 Methodology& Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculation
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of parasitic infections
  - 3.2.1.2 Increasing government initiatives and funding
  - 3.2.1.3 Increasing global travel and migration
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Increasing drug resistance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Anthelmintics
5.3 Antiprotozoal
5.4 Ectoparasiticides
5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Injectable
6.3 Oral
6.4 Topical

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of Middle East and Africa